EDI048

Phase 2Small molecule

Novartis

EDI048 is one of 6 small molecule programs targeting Cryptosporidiosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CryptosporidiosisRecruiting

CryptosporidiosisPhase 2

Recruiting

Competition

Competitive Landscape

5 competitors in Cryptosporidiosis

#DrugCompanyPhaseTrials

Zithromax

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

3 2

Cryptosporidium Parvum Oocysts (ABO809)

Novartis

Phase 2

1 3

EDI048

Novartis

Phase 2

1 4

Diclazuril

Johnson & Johnson

Preclinical

2 5

Spiramycin

RRhone-Poulenc Rorer

Preclinical

1 6

Interleukin-12

NNational Institute of Allergy and Infectious Diseases (NIAID)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Recruiting

Cryptosporidiosis

NCT07249463

Clinical

Trials by Indication[1]

Tics1 trial

First in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of EDI048 in Healthy Volunteers

Completed· Novartis logo

Novartis·Phase 1·NCT05275855·110 enrolled

Cryptosporidiosis1 trial

A Randomized, Placebo-controlled, Participant- and Investigator-blinded Study to Assess the Efficacy and Safety and Tolerability of EDI048 in a Cryptosporidium Controlled Human Infection Model (CHIM) in Healthy Participants

Recruiting· Novartis logo

Novartis·Phase 2·NCT07249463·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for EDI048. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — EDI048 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for EDI048. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Novartis

EDI048

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Tics1 trial

Cryptosporidiosis1 trial

References

Drug Info

Quick Facts

Related News